Clinical Report: Two General Sessions, One Reason to Be in Montréal

Overview

The 2026 Annual Meeting will feature keynotes and sessions focusing on advancements in pathology and laboratory medicine, including discussions on CAR-T therapy and digital pathology.

Background

The joint meeting of ASCP and CAP-ACP highlights the importance of continuous education in pathology and laboratory medicine.

Data Highlights

No numerical data or trial data available in the source material.

Key Findings

• Donald L. Siegel will keynote on CAR-T therapy.
• Pathology has played a role in the development of CAR-T therapies.
• General sessions will cover digital pathology, precision diagnostics, workload, burnout, and patient advocacy.
• Monalisa Sur will discuss key initiatives in pathology and laboratory medicine.

Clinical Implications

Attendees will learn about advancements in CAR-T therapy and digital pathology.

Conclusion

The 2026 Annual Meeting serves as a platform for discussing advancements in pathology.

Related Resources & Content

1. ASCP, ASCP News, 2026 -- Leading Edge Scientist Dr. Donald L. Siegel, and CAP-ACP Subject Matter Experts, to Keynote the 2026 Annual Meeting
2. retinal physician — What to Expect at ASRS 2026
3. Drug Safety — Outcomes from the 2023 National Conference of the Canadian Medication Appropriateness and Deprescribing Network
4. the analytical scientist — Eight Tips for Easy GC×GC
5. Contact Lens Spectrum — A Look at 25 Years of GSLS and Specialty Lenses
6. Laboratory Developed Tests | FDA
7. Standards for Blood Banks and Transfusion Services
8. M100 | Performance Standards for Antimicrobial Susceptibility Testing
9. CAP Updates Cancer Protocols To Advance Breast Cancer Biomarker Reporting And GIST Molecular Testing - CAP
10. Publication of the WHO Classification of Tumours, 6th Edition, Volume 1: Digestive System Tumours – IARC
11. Interpretive Diagnostic Error Reduction - CAP
12. Prehospital Resuscitation with Type O Whole Blood for Trauma and Hemorrhage | New England Journal of Medicine
13. Balanced Component and Whole-Blood Transfusion Practices in US Trauma Centers | Emergency Medicine | JAMA Network Open | JAMA Network
14. ASTCT Consensus Grading for Toxicities after Immune Effector Cell Therapy - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy
15. Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0
16. Leading Edge Scientist Dr. Donald L. Siegel, and CAP-ACP Subject Matter Experts, to Keynote the 2026 Annual Meeting